Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride in Asian patients with CRPC
NCT01810770Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2013
- Primary completion
- Sep 2017
- Modality
- Radiopharmaceutical
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Primary endpoints: Number of participants with adverse events as a measure of safety and tolerability up to 36 months, Number of participants with laboratory changes up to 36 months and 3 more. Started Mar 2013; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01810770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810770.